Vistagen Therapeutics Gains Momentum; Blend Labs Beats Estimates
- August 10th, 2023
- 428 views
Shares of Vistagen Therapeutics, Inc. (Nasdaq: VTGN) surged over 20% in after-hours trading as Commodore Capital LP disclosed in a regulatory filing (Form 4) with the SEC that it has recently acquired 775,756 shares of Vistagen through multiple transactions, at an average price of $23.153 per share.
The late clinical-stage biopharmaceutical company will be reporting its first-quarter fiscal-year 2024 financial results after the market closes on Thursday, August 10.
$VTGN was trading at $8.65 in after-hours, reflecting a significant increase of $1.61 or 22.96%.
In other news, Blend Labs, Inc. (NYSE: BLND) reported better-than-expected second-quarter 2023 financial results. The company's loss per share came in at $(0.09), outperforming the consensus estimate loss of $(0.13). In addition, Blend Labs achieved quarterly sales of $42.81 million, surpassing analysts' projected revenue of $40.11 million for the period.
In after-hours, $BLND was trading at $1.46, up $0.24 (+19.67%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login